No Data
No Data
J.P. Morgan Maintains Repligen(RGEN.US) With Buy Rating, Cuts Target Price to $190
Peptide Therapeutics Industry Report 2024, Featuring Profiles of 30+ Leading Players Including PeptiDream, PolyPeptide, Repligen, X-GEN Pharmaceuticals, Zydus Cadila and More
At US$139, Is Repligen Corporation (NASDAQ:RGEN) Worth Looking At Closely?
Wolfe's Tax Loss Selling Stocks Within Communications, Discretionary, Staples, Energy, Financials, Health Care
Morgan Stanley Identifies 39 Stocks Likely to Face Tax Loss Selling Pressure
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA) and Repligen (RGEN)
No Data
No Data